Senesco Technologies Reports Second Quarter Fiscal 2008 Financi...(eously with human multiple myeloma...)

with human multiple myeloma cancer cells to form myeloma tumors in

their flanks. Treated mice were injected intratumorally with Factor 5A

therapy encapsulated in nanoparticles, while control mice received a

nanoparticle without the Factor 5A therapy. One of the dosing regimens

showed evidence of significant tumor regression relative to the

untreated control mice, while the other showed a diminished rate of

tumor growth along with some regression.

"As our recent accomplishments indicate, we continue to execute on our strategy," said Bruce Galton, President and CEO of Senesco. We believe we have advanced our human health preclinical research program via the selection of a CRO and the successful completion of certain in-vivo preclinical studies in multiple myeloma. Our objectives for the remainder of the year are to continue to evaluate dosing regimens and encapsulation vehicles in preclinical multiple myeloma cancer models, to identify contract manufacturing centers to produce cGMP materials, to plan and carry out the necessary toxicology studies, and to work with our CRO to begin preparation of an Investigational New Drug Application."

-- Revenue of $6,250 for the three month period ended December 31, 2007

consisted of the amortized portion of previous milestone payments

received in connection with certain license agreements. During the

three-month period ended December 31, 2006, revenue of $181,250

consisted of initial fees, milestone payments and the amortized portion

of previous milestone payments received in connection with certain

development and license agreements.

-- Research and development expenses during the three month period ended

December 31, 2007 were $392,254, compared with $239,395 during the

three month period ended December 31, 2006. This increase resulted

from an incre
'/>"/>